Sponsor |  squiffy2 | Jul 18, 1:30am |
BioMS Medical Corp. announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 (dirucotide) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.
This was the fifth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial....................
For the full report please go to MSRC: MS Research News : Drugs : MBP8298 - msrc.co.uk/index.cfm [msrc.co.uk/index.cfm]
|
|
Multiple Sclerosis → Discussion